RxDoctor Payments Data

Ryan Dunn, NP

Nurse Practitioner · Evansville, INNPI 1881392439

Payments from drug & device makers

$4,033in general payments, 2019–2025

Across 227 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$379
  • AstraZeneca$347
  • Novo Nordisk$289
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$250
  • Novartis$239
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,033 in reported general payments places this provider in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$44,306
Medicare patients
161
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$39,956
VraylarCariprazine Hcl16$22,292
JardianceEmpagliflozin34$22,189
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,815
FarxigaDapagliflozin Propanediol13$8,561
Gabapentin61$1,295
Atorvastatin Calcium85$587
Levothyroxine Sodium35$534
Duloxetine Hcl18$490
Albuterol Sulfate HfaAlbuterol Sulfate40$483
Fluticasone Propionate46$475
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav58$450
Omeprazole41$406
Chlorthalidone21$350
Pregabalin11$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$289$39,95636 claims
AbbVieVraylar$1,075$22,29216 claims
Boehringer IngelheimJardiance$18$22,18934 claims
AstraZenecaBreztri Aerosphere, Farxiga$347$18,37629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →